Concepedia
Statistics
Publications
27
Citations
3.5K
H-Index
25
Active since
1990
Affiliations
Novartis (Switzerland)(Current)
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Novartis Institutes for BioMedical Research
Howard Hughes Medical Institute
Johannes Roesel is an author at Novartis (Switzerland) specializing in pharmacology, oncology, and tyrosine kinase inhibitors.
Publications per year
1990–2018
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Taro Hitosugi, Sumin Kang, Matthew G. Vander Heiden et al. · Science Signaling · 2009 · 781 citations · Full text
Life Sciences, Cancer Biology, Oncology +17
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · Gastroenterology · 2005 · 494 citations · Full text
Medicine, Oncology, Pharmacology +15
Tyrosine Phosphorylation of Mitochondrial Pyruvate Dehydrogenase Kinase 1 Is Important for Cancer Metabolism
Taro Hitosugi, Jun Fan, Tae‐Wook Chung et al. · Molecular Cell · 2011 · 344 citations · Full text
Life Sciences, Biochemistry, Oncology +17
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
Florian H. Heidel, Fian K. Solem, Frank Breitenbuecher et al. · Blood · 2005 · 268 citations
Medicine, Oncology, Pharmacology +17
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Urs Eppenberger, Willy Kueng, Jean-Marc Schlaeppi et al. · Journal of Clinical Oncology · 1998 · 220 citations
Medicine, Cancer Biology, Oncology +17
1–5 of 27